Skip to main content
OpenTrials

Clinical trial condition

Kidney Neoplasms

Explore clinical trials studying Kidney Neoplasms. Study availability and eligibility vary by location and protocol.

1,142 public trials 219 recruiting studies
Refine in advanced search Browse all conditions

Kidney Neoplasms trial results

Completed

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer

NCT00006251

Conditions
Acute Undifferentiated Leukemia, Adenocarcinoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, +152 more
Locations
  • Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States
  • University of Torino Torino, Italy
View Trial Details
Completed

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

NCT00078858

Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adenocarcinoma, Adult Acute Lymphoblastic Leukemia in Remission, +220 more
Locations
  • Stanford University Hospitals and Clinics Stanford, California, United States
  • Rocky Mountain Cancer Centers-Midtown Denver, Colorado, United States
  • Emory University/Winship Cancer Institute Atlanta, Georgia, United States
  • OHSU Knight Cancer Institute Portland, Oregon, United States
View Trial Details
Completed

Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)

NCT01550367

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Loyola University Chicago Maywood, Illinois, United States
  • Indiana University Simon Cancer Center Indianapolis, Indiana, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Dartmouth-Hitchcock Medical Center Hanover, New Hampshire, United States
View Trial Details
Completed

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma

NCT01984242

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • HonorHealth Research Institute - Bisgrove Scottsdale, Arizona, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • UCLA Los Angeles, California, United States
  • University of California San Francisco, California, United States
View all 45 locations
View Trial Details

Related conditions